Trial · NCT07502976
Topical 2-Deoxy-D-ribose Hydrogel Versus Minoxidil 5% Solution for Androgenetic Alopecia
NCT07502976, Not applicable, Recruiting, Kasr El Aini Hospital
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Topical 2-Deoxy-D-ribose Hydrogel Versus Minoxidil 5% Solution for Androgenetic Alopecia. Trials, record NCT07502976. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07502976
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Topical 2-Deoxy-D-ribose Hydrogel Versus Minoxidil 5% Solution for Androgenetic Alopecia
- NCT number
- NCT07502976
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 60 participants, estimated
- Lead sponsor
- Kasr El Aini Hospital
- Conditions
- Androgenic Alopecia
- Interventions
- Topical 2-Deoxy-D-ribose Hydrogel, Topical Minoxidil 5% Solution
- First posted
- 2026-03-31
- Last updated
- 2026-04-06
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Terminal Hair Density | Baseline to Week 12 | Change in terminal hair density in the predefined trichoscopic assessment areas after 12 weeks of treatment, compared between the topical 2-Deoxy-D-ribose hydrogel group and the topical minoxidil 5% solution group. |
| Primary | Change in Total Hair Density | Baseline to Week 12 | Change in total hair density in the predefined trichoscopic assessment areas after 12 weeks of treatment, compared between the topical 2-Deoxy-D-ribose hydrogel group and the topical minoxidil 5% solution group. |
| Primary | Change in Tissue VEGF Level | Baseline to Week 12 | Change in tissue vascular endothelial growth factor (VEGF) levels from baseline to Week 12, measured using scalp biopsy specimens in both treatment groups. |
| Secondary | Change in Terminal Hair Density at Week 24 | Baseline to Week 24 | Change in terminal hair density in the predefined trichoscopic assessment areas after 24 weeks of treatment, compared between the topical 2-Deoxy-D-ribose hydrogel group and the topical minoxidil 5% solution group. |
| Secondary | Change in Total Hair Density at Week 24 | Baseline to Week 24 | Change in total hair density in the predefined trichoscopic assessment areas after 24 weeks of treatment, compared between the topical 2-Deoxy-D-ribose hydrogel group and the topical minoxidil 5% solution group. |
| Secondary | Global Photographic Assessment | Week 12 and Week 24 | Change in standardized scalp photographs assessed independently by 3 blinded dermatologists using a 7-point modified physician global assessment scale ranging from -3 (significant disease progression) to 3 (excellent improvement). |
| Secondary | Patient Global Assessment | Week 12 and Week 24 | Participant-reported overall improvement using a 5-point scale: 0 = no improvement, 1 = mild response (less than 25%), 2 = moderate response (25% to 49%), 3 = good response (50% to 74%), and 4 = very good response (75% or more). |
| Secondary | Patient Satisfaction Score | Week 12 and Week 24 | Participant-reported treatment satisfaction using a 10-point visual analogue scale ranging from 0 (not satisfied at all) to 10 (completely satisfied). |
| Secondary | Incidence of Treatment-Emergent Adverse Events | Baseline to Week 24 | Safety assessment of topical 2-Deoxy-D-ribose hydrogel based on adverse events, including erythema, itching, pain, allergic or irritant contact dermatitis, and undesirable hair texture, as evaluated through participant history, diary records, and clinical scalp examination. |
| Secondary | Correlation of Treatment Response With Clinical and Demographic Variables | Baseline to Week 24 | Association between treatment response and selected clinical and demographic variables collected during the study. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07502976
GET https://conductscience.org/api/trials/v1/NCT07502976/registered